NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Caporali, Simona ^a   Levati, Lauretta ^a   Graziani, Grazia ^b   Muzi, Alessia ^b   Atzori, Maria Grazia ^a   Bonmassar, Enzo ^b,c   Palmieri, Giuseppe ^d   Ascierto, Paolo A ^e   D'Atri, Stefania ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^d CNR   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

AKT; Cell proliferation; Cell senescence; NEMO binding domain peptide; Nuclear factor B; Temozolomide

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN 2; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; PROTEIN P52; SMALL INTERFERING RNA; TEMOZOLOMIDE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; DACARBAZINE; DRUG DERIVATIVE; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PEPTIDE;

ARTICLE; CANCER CELL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE SILENCING; GENE TARGETING; GENE TRANSLOCATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOMA METASTASIS; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; WILD TYPE; CELL AGING; CELL NUCLEUS; CELL PROLIFERATION; CELL PROTECTION; CELL STRAIN HCT116; CELL STRAIN HEK293; CELL STRAIN MCF 7; DRUG EFFECT; DRUG SCREENING; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MISMATCH REPAIR; PHOSPHORYLATION; PROTEIN TRANSPORT; RNA INTERFERENCE;

CELL AGING; CELL NUCLEUS; CELL PROLIFERATION; CYTOPROTECTION; DACARBAZINE; DNA MISMATCH REPAIR; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HEK293 CELLS; HUMANS; I-KAPPA B PROTEINS; MCF-7 CELLS; NF-KAPPA B; PEPTIDES; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC;

MLCS; MLOWN;

EID: 84871372401     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-252     Document Type: Article

References (67)

1. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-kB addiction and its role in cancer: 'one size does not fit all'. Oncogene 2011, 30:1615-1630. 10.1038/onc.2010.566, 3141287, 21170083.
2. DiDonato JA, Mercurio F, Karin M. NF-kB and the link between inflammation and cancer. Immunol Rev 2012, 246:379-400. 10.1111/j.1600-065X.2012.01099.x, 22435567.
3. Perkins ND. The diverse and complex roles of NF-kB subunits in cancer. Nat Rev Cancer 2012, 12:121-132.
4. Sun SC. The noncanonical NF-kB pathway. Immunol Rev 2012, 246:125-140. 10.1111/j.1600-065X.2011.01088.x, 22435551.
5. Wu ZH, Miyamoto S. Many faces of NF-kB signaling induced by genotoxic stress. J Mol Med (Berl) 2007, 85:1187-1202.
6. Sabatel H, Pirlot C, Piette J, Habraken Y. Importance of PIKKs in NF-kB activation by genotoxic stress. Biochem Pharmacol 2010, 82:1371-1383.
7. Miyamoto S. Nuclear initiated NF-kB signaling: NEMO and ATM take center stage. Cell Res 2011, 21:116-130. 10.1038/cr.2010.179, 3193401, 21187855.
8. Barrè B, Coqueret O, Perkins ND. Regulation of activity and function of the p52 NF-kB subunit following DNA damage. Cell Cycle 2010, 9:4795-4804. 10.4161/cc.9.24.14245, 21131783.
9. Payne MJ, Pratap SE, Middleton MR. Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol 2005, 53:241-252. 10.1016/j.critrevonc.2004.10.004, 15718149.
10. Bei R, Marzocchella L, Turriziani M. The use of temozolomide for the treatment of malignant tumors: clinical evidence and molecular mechanisms of action. Recent Pat Anticancer Drug Discov 2010, 5:172-187. 10.2174/157489210791760526, 20594183.
11. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006, 7:335-346.
12. Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res 2008, 18:85-98. 10.1038/cr.2007.115, 18157157.
13. Kaina B, Ziouta A, Ochs K, Coquerelle T. Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models. Mutat Res 1997, 381:227-241. 10.1016/S0027-5107(97)00187-5, 9434879.
14. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E, Jiricny J. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998, 54:334-341.
15. Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001, 61:1957-1963.
16. Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper RO. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol 2003, 23:8306-8315. 10.1128/MCB.23.22.8306-8315.2003, 262371, 14585987.
17. Stojic L, Mojas N, Cejka P, Di Pietro M, Ferrari S, Marra G, Jiricny J. Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev 2004, 18:1331-1344. 10.1101/gad.294404, 420358, 15175264.
18. Caporali S, Falcinelli S, Starace G, Russo MT, Bonmassar E, Jiricny J, D'Atri S. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol 2004, 66:478-491.
19. Kim WJ, Rajasekaran B, Brown KD. MLH1- and ATM-dependent MAPK signaling is activated through c-Abl in response to the alkylator N-methyl-N'-nitro-N'-nitrosoguanidine. J Biol Chem 2007, 282:32021-32031. 10.1074/jbc.M701451200, 17804421.
20. Kaina B, Margison GP, Christmann M. Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol Life Sci 2010, 67:3663-3681. 10.1007/s00018-010-0491-7, 20717836.
21. Pegg AE. Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools. Chem Res Toxicol 2011, 24:618-639. 10.1021/tx200031q, 3095683, 21466232.
22. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562. 10.1038/nrc2664, 19629070.
23. Perkins ND. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 2006, 25:6717-6730. 10.1038/sj.onc.1209937, 17072324.
24. Gustin JA, Korgaonkar CK, Pincheira R, Li Q, Donner DB. Akt regulates basal and induced processing of NF-kB2 (p100) to p52. J Biol Chem 2006, 281:16473-16481. 10.1074/jbc.M507373200, 16613850.
25. Caporali S, Levati L, Starace G, Ragone G, Bonmassar E, Alvino E, D'Atri S. AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol Pharmacol 2008, 74:173-183. 10.1124/mol.107.044743, 18413665.
26. Golub SH, Hanson DC, Sulit HL, Morton DL, Pellegrino MA, Ferrone S. Comparison of histocompatibility antigens on cultured human tumor cells and fibroblasts by quantitative antibody absorption and sensitivity to cell-mediated cytotoxicity. J Natl Cancer Inst 1976, 56:167-170.
27. Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994, 263:1625-1629. 10.1126/science.8128251, 8128251.
28. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, Boland CR. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N'-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 1994, 54:4308-4312.
29. Cejka P, Stojic L, Mojas N, Russell AM, Heinimann K, Cannavò E, di Pietro M, Marra G, Jiricny J. Methylation-induced G2/M arrest requires a full complement of the mismatch repair protein hMLH1. EMBO J 2003, 22:2245-2254. 10.1093/emboj/cdg216, 156088, 12727890.
30. Pepponi R, Marra G, Fuggetta MP, Falcinelli S, Pagani E, Bonmassar E, Jiricny J, D'Atri S. The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther 2003, 304:661-668. 10.1124/jpet.102.043950, 12538819.
31. Vernole P, Pepponi R, D'Atri S. Role of mismatch repair in the induction of chromosomal aberrations and sister chromatid exchanges in cells treated with different chemotherapeutic agents. Cancer Chemother Pharmacol 2003, 52:185-192. 10.1007/s00280-003-0660-6, 12827294.
32. Clemons M, Kelly J, Watson AJ, Howell A, McElhinney RS, McMurry TB, Margison GP. O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. Br J Cancer 2005, 93:1152-1156. 10.1038/sj.bjc.6602833, 2361498, 16278661.
33. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, Santarius T, Avis T, Barthorpe S, Brackenbury L, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006, 5:2606-2612. 10.1158/1535-7163.MCT-06-0433, 2705832, 17088437.
34. Colombino M, Sperlongano P, Izzo F, Tatangelo F, Botti G, Lombardi A, Accardo M, Tarantino L, Sordelli I, Agresti M, et al. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis 2012, 3:e259. 10.1038/cddis.2011.136, 3270270, 22258409.
35. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S. Selective inhibition of NF-kB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000, 289:1550-1554. 10.1126/science.289.5484.1550, 10968790.
36. Madonna S, Scarponi C, Sestito R, Pallotta S, Cavani A, Albanesi C. The IFN-g-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and Kruppel-like factor-4, and it is dysregulated in psoriatic keratinocytes. J Immunol 2010, 185:2467-2481. 10.4049/jimmunol.1001426, 20644166.
37. Kunsch C, Rosen CA. NF-kB subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol 1993, 13:6137-6146. 364673, 8413215.
38. Ueda A, Okuda K, Ohno S, Shirai A, Igarashi T, Matsunaga K, Fukushima J, Kawamoto S, Ishigatsubo Y, Okubo T. NF-kB and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol 1994, 153:2052-2063.
39. Romashkova JA, Makarov SS. NF-kB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401:86-90. 10.1038/43474, 10485711.
40. Yang CH, Murti A, Pfeffer SR, Kim JG, Donner DB, Pfeffer LM. Interferon a/b promotes cell survival by activating nuclear factor kB through phosphatidylinositol 3-kinase and Akt. J Biol Chem 2001, 276:13756-13761.
41. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401:82-85. 10.1038/43466, 10485710.
42. Sethi G, Ahn KS, Sung B, Kunnumakkara AB, Chaturvedi MM, Aggarwal BB. SH-5, an AKT inhibitor potentiates apoptosis and inhibits invasion through the suppression of anti-apoptotic, proliferative and metastatic gene products regulated by IkBa kinase activation. Biochem Pharmacol 2008, 76:1404-1416. 10.1016/j.bcp.2008.05.023, 18606397.
43. Kane LP, Mollenauer MN, Xu Z, Turck CW, Weiss A. Akt-dependent phosphorylation specifically regulates Cot induction of NF-kB-dependent transcription. Mol Cell Biol 2002, 22:5962-5974. 10.1128/MCB.22.16.5962-5974.2002, 133991, 12138205.
44. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin AS. Akt-dependent regulation of NF-kB is controlled by mTOR and Raptor in association with IKK. Genes Dev 2008, 22:1490-1500. 10.1101/gad.1662308, 2418585, 18519641.
45. Sun SC, Ganchi PA, Ballard DW, Greene WC. NF-kappaB controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science 1993, 259:1912-1915. 10.1126/science.8096091, 8096091.
46. Mhaidat NM, Zhang XD, Allen J, Avery-Kiejda KA, Scott RJ, Hersey P. Temozolomide induces senescence but not apoptosis in human melanoma cells. Br J Cancer 2007, 97:1225-1233. 10.1038/sj.bjc.6604017, 2360470, 17968428.
47. Boland MP, Foster SJ, O'Neill LA. Daunorubicin activates NFkB and induces kB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells. J Biol Chem 1997, 272:12952-12960. 10.1074/jbc.272.20.12952, 9148901.
48. Bottero V, Busuttil V, Loubat A, Magne N, Fischel JL, Milano G, Peyron JF. Activation of nuclear factor kB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res 2001, 61:7785-7791.
49. Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, Kalyanaraman B. Activation of nuclear factor-kB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem J 2002, 367:729-740. 10.1042/BJ20020752, 1222928, 12139490.
50. Wu ZH, Miyamoto S. Induction of a pro-apoptotic ATM-NF-kB pathway and its repression by ATR in response to replication stress. EMBO J 2008, 27:1963-1973. 10.1038/emboj.2008.127, 2486281, 18583959.
51. Smale ST. Dimer-specific regulatory mechanisms within the NF-kB family of transcription factors. Immunol Rev 2012, 246:193-204. 10.1111/j.1600-065X.2011.01091.x, 22435556.
52. Richmond A, Yang J, Su Y. The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res 2009, 22:175-186. 10.1111/j.1755-148X.2009.00554.x, 2848967, 19222802.
53. Gustin JA, Ozes ON, Akca H, Pincheira R, Mayo LD, Li Q, Guzman JR, Korgaonkar CK, Donner DB. Cell type-specific expression of the IkB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kB activation. J Biol Chem 2004, 279:1615-1620. 10.1074/jbc.M306976200, 14585846.
54. Madrid LV, Mayo MW, Reuther JY, Baldwin AS. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kB through utilization of the IkB kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 2001, 276:18934-18940. 10.1074/jbc.M101103200, 11259436.
55. Bai D, Ueno L, Vogt PK. Akt-mediated regulation of NFkB and the essentialness of NFkB for the oncogenicity of PI3K and Akt. Int J Cancer 2009, 125:2863-2870. 10.1002/ijc.24748, 2767458, 19609947.
56. Ianaro A, Tersigni M, Belardo G, Di Martino S, Napolitano M, Palmieri G, Sini M, De Maio A, Ombra M, Gentilcore G, et al. NEMO-binding domain peptide inhibits proliferation of human melanoma cells. Cancer Lett 2009, 274:331-336. 10.1016/j.canlet.2008.09.038, 19004544.
57. Ueda Y, Richmond A. NF-kB activation in melanoma. Pigment Cell Res 2006, 19:112-124. 10.1111/j.1600-0749.2006.00304.x, 2668252, 16524427.
58. Madonna G, Ullman CD, Gentilcore G, Palmieri G, Ascierto PA. NF-kB as potential target in the treatment of melanoma. J Transl Med 2012, 10:53. 10.1186/1479-5876-10-53, 3338086, 22433222.
59. Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004, 64:4912-4918. 10.1158/0008-5472.CAN-04-0673, 15256463.
60. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011, 11:239-253. 10.2174/156800911794519752, 3306611, 21247388.
61. Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari J, Bille K, Robert C, Bressac-de Paillerets B, Bressac-de Paillerets P, et al. Senescent cells develop a PARP-1 and nuclear factor-kB-associated secretome (PNAS). Genes Dev 2011, 25:1245-1261. 10.1101/gad.625811, 3127427, 21646373.
62. Yamini B, Yu X, Dolan ME, Wu MH, Darga TE, Kufe DW, Weichselbaum RR. Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding. Cancer Res 2007, 67:6889-6898. 10.1158/0008-5472.CAN-06-4496, 17638900.
63. Schmitt AM, Crawley CD, Kang S, Raleigh DR, Yu X, Wahlstrom JS, Voce DJ, Darga TE, Weichselbaum RR, Yamini B. p50 (NF-kB1) is an effector protein in the cytotoxic response to DNA methylation damage. Mol Cell 2011, 44:785-796. 10.1016/j.molcel.2011.09.026, 3240852, 22152481.
64. Hirose Y, Katayama M, Mirzoeva OK, Berger MS, Pieper RO. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res 2005, 65:4861-4869. 10.1158/0008-5472.CAN-04-2633, 15930307.
65. Shtivelman E, Sussman J, Stokoe D. A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol 2002, 12:919-924. 10.1016/S0960-9822(02)00843-6, 12062056.
66. Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L, Mansukhani M, Murty VV, Gaciong Z, Meek SE, et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 2005, 7:193-204. 10.1016/j.ccr.2005.01.009, 15710331.
67. Barrè B, Perkins ND. A cell cycle regulatory network controlling NF-kB subunit activity and function. EMBO J 2007, 26:4841-4855. 10.1038/sj.emboj.7601899, 2099464, 17962807.